Hennion & Walsh Asset Management Inc. Raises Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Hennion & Walsh Asset Management Inc. boosted its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 16.9% during the first quarter, Holdings Channel.com reports. The fund owned 184,815 shares of the biopharmaceutical company’s stock after purchasing an additional 26,761 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in TG Therapeutics were worth $2,811,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in TGTX. Pingora Partners LLC acquired a new position in shares of TG Therapeutics in the 4th quarter valued at about $27,000. PNC Financial Services Group Inc. raised its holdings in TG Therapeutics by 131.7% in the third quarter. PNC Financial Services Group Inc. now owns 3,543 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 2,014 shares during the period. Anchor Investment Management LLC acquired a new position in TG Therapeutics during the fourth quarter valued at approximately $80,000. Sherbrooke Park Advisers LLC purchased a new stake in TG Therapeutics during the third quarter worth approximately $104,000. Finally, Kestra Advisory Services LLC lifted its holdings in TG Therapeutics by 8.2% in the 3rd quarter. Kestra Advisory Services LLC now owns 16,342 shares of the biopharmaceutical company’s stock worth $137,000 after buying an additional 1,240 shares in the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Stock Down 0.9 %

NASDAQ:TGTX traded down $0.16 during mid-day trading on Friday, reaching $17.79. The stock had a trading volume of 3,138,484 shares, compared to its average volume of 2,332,902. The stock’s 50 day simple moving average is $16.45 and its two-hundred day simple moving average is $16.08. TG Therapeutics, Inc. has a 1-year low of $6.46 and a 1-year high of $26.95. The company has a market capitalization of $2.75 billion, a price-to-earnings ratio of 77.35 and a beta of 2.30. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.62 and a quick ratio of 2.84.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The firm had revenue of $63.47 million during the quarter, compared to the consensus estimate of $54.60 million. TG Therapeutics had a net margin of 14.24% and a return on equity of 31.34%. TG Therapeutics’s revenue was up 713.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.28) earnings per share. Equities analysts anticipate that TG Therapeutics, Inc. will post -0.01 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on TGTX shares. HC Wainwright raised their target price on TG Therapeutics from $45.00 to $49.00 and gave the company a “buy” rating in a research note on Thursday, May 2nd. JPMorgan Chase & Co. restated an “overweight” rating and set a $25.00 price objective on shares of TG Therapeutics in a research note on Thursday, April 18th. Finally, LADENBURG THALM/SH SH upped their target price on TG Therapeutics from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, May 2nd. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $29.83.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.